As reported earlier, these mice developed cardiac pathologies characteristic of HFpEF over time, including preserved ejection fraction and fraction shortening (Figure 2 C and S1A) , elevated E/e' ratio (Figure 2 D) and prolonged isovolumic relaxation time (IVRT) as early as 8 weeks after L-NAME/HFD treatment ( Figure S1 B) , along with an increasing trend in the E/A ratio ( Figure S1 C) .
← all excerpts
BCAA catabolism targeted therapy for heart failure with preserved ejection fraction.
1
—
—